공지 • Apr 21
NexgenRx Inc. announces Semi-Annual dividend, payable on April 28, 2026 NexgenRx Inc. announced Semi-Annual dividend of CAD 0.0050 per share payable on April 28, 2026, ex-date on April 24, 2026 and record date on April 24, 2026. 공지 • Apr 02
NexgenRx Inc., Annual General Meeting, May 21, 2026 NexgenRx Inc., Annual General Meeting, May 21, 2026. 공지 • Dec 12
NexgenRx Inc. announces Semi-Annual dividend, payable on December 19, 2025 NexgenRx Inc. announced Semi-Annual dividend of CAD 0.0050 per share payable on December 19, 2025, ex-date on December 17, 2025 and record date on December 17, 2025. 공지 • Aug 19
NexgenRx Inc. announces Semi-Annual dividend, payable on August 29, 2025 NexgenRx Inc. announced Semi-Annual dividend of CAD 0.0050 per share payable on August 29, 2025, ex-date on August 25, 2025 and record date on August 25, 2025. 공지 • Apr 18
Nexgenrx Inc. Declares Dividend on Common Shares, Payable on or before April 30, 2025 NEXGENRX INC. announced that a dividend in the amount of one-half of one cent per share ($0.005) has been declared in respect of all of its outstanding common shares. The dividend will be payable on or before April 30, 2025 to all shareholders of record as at the close of business on April 25, 2025. 공지 • Mar 28
NexgenRx Inc., Annual General Meeting, May 15, 2025 NexgenRx Inc., Annual General Meeting, May 15, 2025. 공지 • Nov 26
Nexgenrx Inc. Declares Dividend on Common Shares, Payable on or Before December 20, 2024 NexgenRx Inc. announced a dividend in the amount of one-half of one cent per share ($0.005) has been declared in respect of all of the Company's outstanding common shares. The dividend will be payable on or before December 20, 2024 to all shareholders of record as at the close of business on December 16, 2024. 공지 • Oct 01
NexgenRx Inc. Announces Appointment of Linda Brennan to Its Board of Directors NexgenRx Inc. announced the appointment of Linda Brennan to its Board of Directors effective immediately. Linda Brennan currently serves as Chief Financial Officer, Corporate Secretary and a Director of PJX Resources Inc. Ms. Brennan has been a consultant for 12 years, providing strategic advice and organizing and structuring financings to numerous early stage companies in the junior resource sector. She brings knowledge of finance, accounting and public markets to NexgenRx. She has served in the capacity of corporate secretary for several TSX-V listed companies. Ms. Brennan holds Business Administration and Bachelor of Commerce degrees from the University of Victoria and Royal Roads University, respectively. 공지 • Jun 15
NexgenRx Inc. Declares Dividend in Respect of All of Its Outstanding Common Shares, Payable on or Before June 30, 2024 NEXGENRX INC. announced that a dividend in the amount of $0.005 has been declared in respect of all of its outstanding common shares. This dividend will be payable on or before June 30, 2024 to all shareholders of record as at the close of business on June 24, 2024. 공지 • May 18
Charles Burns Tenders Resignation as Director of NexgenRx Inc NexgenRx Inc. announced that at the annual and special meeting of shareholders held on May 16, 2024, one of the Directors, Charles Burns was duly elected although the number of votes 'Withheld' exceeded the number of votes cast 'For' his election and based on the Company's Majority Voting Policy, Mr. Burns has tendered his resignation as a director of the Company. The Board has determined to delay acceptance of Mr. Burns' resignation until such time as a qualified candidate can be appointed to fill the vacancy created by this resignation, which is expected to occur on or before September 30, 2024. 공지 • Apr 03
NexgenRx Inc., Annual General Meeting, May 16, 2024 NexgenRx Inc., Annual General Meeting, May 16, 2024. 공지 • Dec 30
NEXGENRX INC. Announces the Retirement of Dave Bennett from its Board of Directors NEXGENRX INC. announced the retirement of Dave Bennett from its Board of Directors as he has accepted a senior executive role in the industry and as such will be devoting 100% of his time to this new endeavour. 공지 • Dec 21
NEXGENRX Inc Announces Declaration of Dividend, Payable on or Before January 4, 2024 NEXGENRX INC announced that a dividend in the amount of one-half of one cent per share ($0.005) has been declared in respect of all of its outstanding common shares and series 1 preferred shares. This dividend will be payable on or before January 4, 2024 to all shareholders of record as at the close of business on December 29, 2023. 공지 • Jun 16
NexgenRx Inc. Announces Declaration of Dividend in Respect of All of Its Outstanding Common Shares , Payable on or Before June 30, 2023 NEXGENRX INC. announced that a dividend in the amount of one-half of one cent per share ($0.005) has been declared in respect of all of its outstanding common shares and series 1 preferred shares. This dividend will be payable on or before June 30, 2023 to all shareholders of record as at the close of business on June 23, 2023. As of the date of this press release, there are a total of 70,335,883 common shares and 6,600,000 series 1 preferred shares issued and outstanding. 공지 • May 19
NexgenRx Inc. Appoints Dave Bennett as New Director NexgenRx Inc. at its AGM held on May 19, 2023, approved the election of Mr. Dave Bennett as new director. Mr. Bennett is a seasoned senior executive and actuary with more than 30 years' experience working in the life insurance and wealth management industries. Most recently, he was at The Equitable Life of Canada, where he led the Group Benefits business for six years. Prior to that, he was the Chief Financial Officer of the company, responsible for all financial oversight, strategic planning and corporate business development. He also has extensive experience in strategy, with time spent at McKinsey & Co, and led the Mergers and Acquisitions function at Manulife. Mr. Bennett attained his ICD.D in 2022 and has served on a number of not-for-profit boards such as Grand River Hospital, the Waterloo District School Board, and as the Chair of an independent school. He also has considerable experience working with boards as management, having been accountable to the Audit and Pension committees of Equitable Life's Board of Directors for 7 years, and leading strategic reviews. 